Cerca | Net Pals

EthanWalker ha aggiunto una foto Altre informazioni
2026-10-23 22:16:07 - Translate -

Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe
Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...

0 Commenti 0 condivisioni 7 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!
JamesWilson ha aggiunto una foto Altre informazioni
2026-10-23 19:43:53 - Translate -

Ionis (IONS) partner Roche shows sefaxersen cut IgA nephropathy proteinuria 43.1% in Phase 3
Roche gave the first effect size from its IMAgINATION kidney trial at ASN Kidney Week, a clearer read for Ionis Pharmaceuticals Inc. (IONS) on a partnered drug that carries milestones and royalties. Sefaxersen cut proteinuria by 43.1% against placebo at 37 weeks in a Phase 3 trial in IgA nephropathy, according to data Ionis Pharmaceuticals Inc. (IONS) released on October 23. Roche Holding AG,...

0 Commenti 0 condivisioni 7 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!
RobertMitchell ha aggiunto una foto Health
2026-10-23 19:35:08 - Translate -

Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease tests
Roth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...

0 Commenti 0 condivisioni 6 Views 0 Anteprima

Effettua l'accesso per mettere mi piace, condividere e commentare!